Transactions: Shining a Light on Structure-Based Drug Discovery

ORGANIZERS: STEVE SOSSION & VINCENT STOLL

SATURDAY, JULY 21, 2018

 

Meeting participants working in the area of protein crystallography, cryo-electron microscopy, and with an interest in drug discovery will have an opportunity to learn from experts how cutting edge technologies are being applied to next-generation drug discovery. Unique facets of industrial structural biology will be highlighted in the course of discussing small-molecule hit-finding efforts, such as fragment-based drug discovery, and the integration of structural and computational approaches to facilitate structure-based drug design. The role of structural information in "new" modality discovery such as vaccines, biologics and peptides will also be discussed.  Unique opportunities to increase the breadth and scope of structural impact in drug discovery will be presented in context of new methods to access traditionally challenging targets such as ion channels and GPCRs, and how next generation synchrotrons, XFELs, and serial data collection techniques could play key roles in the future.

 

Transactions 1

START TIME: 9:00 AM

ROOM: GRAND CENTRE

 

Time: 9:30 AM

Duration: 30 Minutes

IMCA-CAT: Accelerating Drug Discovery Through Synchrotron-Based Structural Biology

Lisa J. Keefe, IMCA-CAT / HWI

 

 

Time: 10:00 AM

Duration: 30 Minutes

Systematic analysis of atomic protein-ligand interactions in the PDB

Matthieu Schapira, Structural Genomics Consortium

 

Time: 11:00 AM

Duration: 30 Minutes

X-ray Free Electron Laser: Opportunities for drug discovery.

Michael Hennig, LeadXpro AG

 

Time: 11:30 AM

Duration: 30 Minutes

Achieving higher performance in high-throughput compound and fragment screening campaigns by the use of "Club Class" data collection with Pipedream and CRIMS

Gerard Bricogne, Global Phasing Limited

 

Time: 12:30 PM

Duration: 30 Minutes

Using small molecule crystal structure data to improve drug discovery

Jason Cole, Cambridge Crystallographic Data Centre

 

 

Transactions 2

START TIME: 1:30 PM

ROOM: GRAND CENTRE

 

Time: 1:30 PM

Duration: 30 Minutes

Structure of HIV-1 TAR in Complex with a Lab-Evolved Protein Provides Insight into RNA Recognition and Synthesis of a Constrained Peptide that Impairs Transcription.

Joseph Wedekind, University of Rochester School of Medicine & Dentistry

 

Time: 2:00 PM

Duration: 30 Minutes

Fragment screening for a protein-protein interaction inhibitor to WDR5

Thomas Peat, CSIRO

 

 

Time: 2:30 PM

Duration: 30 Minutes

Make the right measurement - discovery of an allosteric inhibition site for p300-HAT

Anna Gardberg, Constellation Pharmaceuticals

 

Time: 3:30 PM

Duration: 30 Minutes

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

Mark Chiu, Janssen Research & Development

 

Time: 4:00 PM

Duration: 30 Minutes

Development of small molecule inhibitors that target protein-protein interactions in a transcription factor.

Gil Privé, Princess Margaret Cancer Centre

 

Time: 4:30 PM

Duration: 30 Minutes

CryoEM for drug discovery, design, understanding and application.

Giovanna Scapin, Merck & Co., Inc.